THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...

In response to the devastating earthquake that recently struck Myanmar, Western Union today announced that it is offering consumers around the world zero-fee international money transfers1 to the ...

The decline of local journalism is a growing concern, with over 3,200 newspapers shuttered across the U.S. since 2005. This loss has led to increased misinformation, reduced civic engagement, and ...

Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of the T-cell rebalancing therapy, rocatinlimab, in individuals with moderate to severe ...

Rocatinlimab met all co-primary and key secondary endpoints, showing significant efficacy in atopic dermatitis. In SHUTTLE, 52.3% of patients on the higher dose achieved EASI-75, a 28.7% ...

Amgen and Kyowa Kirin Co., Ltd. (Kyowa Kirin) announced new results from the ongoing ROCKET phase 3 clinical trial programme evaluating rocatinlimab, an investigational T-cell rebalancing therapy ...

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule ...

In a report released on March 7, Stephen Barker from Jefferies maintained a Buy rating on Kyowa Kirin Co (KYKOF – Research Report), with a price target of Yen2,500.00. The company’s shares ...

The data drops provide more evidence that the Kyowa Kirin-partnered rocatinlimab improves outcomes in atopic dermatitis, but questions about the positioning of the anti-OX40 antibody versus Sanofi ...